Broadcast Med | New CAR T-Cell Therapy Showing Promise for Relapsed/Refractory AML скачать в хорошем качестве

Broadcast Med | New CAR T-Cell Therapy Showing Promise for Relapsed/Refractory AML

In a phase 1 clinical trial underway exclusively at Roswell Park, is evaluating a new chimeric antigen receptor (CAR) T-cell therapy that could dramatically transform the treatment of relapsed or refractory acute myeloid leukemia (AML). “The only potential for long-term cure of AML has to come from the immune system,” notes Shernan Holtan, MD, Chief of Blood and Marrow Transplantation and Principal Investigator of the clinical trial. 📚 Read more about this breakthrough trial here - https://physicianresources.roswellpar... Learn more about Dr. Shernan Holtan here - https://www.roswellpark.org/shernan-h... Learn more about Dr. Brian Betts here - https://www.roswellpark.org/brian-betts —————————————————— 👉 To learn more about how Roswell Park can help you, or to refer your patient, fill out the form below. https://forms.roswellpark.org/become-...